| Dr Claudio Verdadero Guillermo Jr, MD | |
|
4912 Hwy. 1, Raceland, LA 70394-0390 | |
| (985) 532-5092 | |
| (985) 532-8044 |
| Full Name | Dr Claudio Verdadero Guillermo Jr |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Location | 4912 Hwy. 1, Raceland, Louisiana |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861681504 | NPI | - | NPPES |
| 1124087 | Medicaid | LA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | 03719R (Louisiana) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Claudio Verdadero Guillermo Jr, MD Po Box 390, Raceland, LA 70394-0390 Ph: (985) 532-5092 | Dr Claudio Verdadero Guillermo Jr, MD 4912 Hwy. 1, Raceland, LA 70394-0390 Ph: (985) 532-5092 |
News Archive
The initial chapter of 'Anti-infective Research and Development: Updates on Infection Mechanisms and Treatments' covers the mode of action of natural antimycobacterial compounds such as nordihydroguaiaretic acid, α-mangostin and allicin, as well as antimicrobial peptides and their role in the innate and adaptive immune response leading to the decrease of microbial resistance.
Alere Inc. (NYSE: ALR), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health information, announced today that it has received U.S. Food and Drug Administration (FDA) approval of its pre-market application (PMA) to market Alere Determine™ HIV 1/2 Ag/Ab Combo in the United States for the detection of HIV-1 p24 antigen and antibodies to HIV-1/HIV-2.
A new study which has been conducted at the University of Bologna shows that brief psychological interventions in school may increase well-being among adolescents and these results persist after 6 months
FLX Bio, Inc., a clinical-stage, biopharmaceutical company focused on the development of oral small-molecule drugs that target drivers of cancer and other immune-related disorders, today announced that the first patient has been treated in its Phase 1/2 clinical trial of FLX475 in patients with various advanced cancers. FLX475 is an oral, small molecule CCR4 antagonist that selectively inhibits migration of regulatory T cells into the tumor microenvironment.
During the Fifth Decennial International Conference on Healthcare-Associated Infections, the Society for Healthcare Epidemiology of America and the Association for Professionals in Infection Control and Epidemiology awarded their first Partnership in Prevention Award to the National Guard Health Affairs in Saudi Arabia.
› Verified 3 days ago